Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Victoria Tutag Lehr has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Cynthia L. Arfken

    Wayne State University

    2 shared publications
  • Indulekha Warrier

    Department of Pediatrics, Division of Clinical Pharmacology and Toxicology/Pediatric Pharmacology Research Unit, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI

    2 shared publications
  • Brittany Stewart

    Wayne State University

    1 shared publication
  • Claire Nolan

    From the Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI (VTL)

    1 shared publication
  • Cynthia L Arfken

    Wayne State University Department of Psychiatry and Behavioral Neurosciences

    1 shared publication
  • Dominick P. Trombetta

    Department of Pharmacy Practice Wilkes University, Allied Services Rehabilitation Hospital Wilkes‐Barre Pennsylvania USA

    1 shared publication

Latest Publications

  • The Centers for Disease Control and Prevention opioid guideline revisions and pharmacy practice: An opinion of the American College of Clinical Pharmacy Pain and Palliative Care Practice and Research Network

    by Jessica B. Emshoff, Katherine N. Theken, Katherine M. Juba, Dominick P. Trombetta, Hannah Denham, Megan Carr, Nancy Love, Mackenzie Page, Emily Uebbing, Victoria Tutag Lehr

    The Centers for Disease Control and Prevention revised their Clinical Practice Guideline for Prescribing Opioids for Pain in 2022. This opinion paper was prepared by members of the American College of Clinical Pharmacy (ACCP) Pain and Palliative Care Practice and Research Network (PRN) and provides an overview of updates to the 2022 guidelines, highlighting major changes from the 2016 guidelines and calling attention to the opportunities and challenges for pharmacists in providing patient‐centered care with opioids for pain management. While this paper represents the opinion of the ACCP Pain and Palliative Care PRN, it does not necessarily represent an official ACCP commentary, guideline, or statement of policy or position.


  • Open Access

    The revised CDC Chronic pain guidelines and payer opioid analgesic policies in Michigan

    by Victoria Tutag Lehr, Cynthia L. Arfken

    Background: Publication of the 2016 United States Centers for Disease Control and Prevention (CDC) guideline for prescribing opioids for chronic pain informed restrictive opioid prescribing policies by state specific commercial and public payers. These policies restricted access to opioid analgesics for patients with intractable pain conditions (e.g. sickle cell disease) who had been receiving long-term opioids at dosages exceeding 90 MME/day. The revised 2022 guidelines no longer recommends specific opioid dose limits or duration of therapy for chronic pain, emphasizing individualized therapy. The impact of the revision on payer opioid prescribing policies is unknown. We examined number and type of policies allowing flexibility in opioid daily dosage (morphine milligram equivalent, MME) and duration of therapy following the 2022 CDC revision. Methods: Policies for seven large commercial payers in Michigan and for Medicaid fee-for-service from 2019–2022 were reviewed and categorized. Policies for prior authorization, quantity limits, duration, and opioids > 90 MME/day for chronic pain were documented by year for each individual payer. Results: The eight payers implemented 207 new actions (mean = 10.3 per year) with the least number during 2020 (n = 25) and the most in 2021 (n = 51). The most common action was limitations on number of days for initial prescriptions (n = 40). All payers had opioid limits 50–120 MME/day. For 6/8 payers, the limit was 90 MME/day unchanged from 2016 CDC guidelines. Prior authorization and/or pharmacist-edit policies were required to exceed opioid limits. In 2022, 7/8 payers exempted sickle cell pain from limits versus 5/8 in 2019. Number of days supply for initial prescription depended on formulation, for long-acting opioids 4/8 payers allowed 30-days and 2/8 allowed 90 days. Discussion: The eight commercial and public payers continued to implement complex opioid prescribing policies. Increased flexibility in daily opioid limits and duration of therapy was available only through prior authorization, pharmacist edits or exemption for the diagnosis of sickle cell pain. Conclusion: Payer policy implementation in one state did not reflect the 2022 CDC revised guidelines for individualized opioid prescribing for chronic pain. The impact of slow payer uptake of the 2022 guidelines on patient care is unknown, requiring continuous monitoring.

  • Community Pharmacists’ Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder

    by Victoria Bspharm Tutag Lehr, Claire Nolan

    Objectives: The aims of the study are to evaluate community pharmacists’ knowledge and perceptions regarding buprenorphine for opioid use disorder and their willingness to dispense buprenorphine and to identify opportunities for education. Methods: An electronic survey of Michigan pharmacists (n = 11,123) assessed demographics, training, buprenorphine knowledge, dispensing, perceptions of stigma, diversion, and confidence in patient/provider interactions. Composite scores for knowledge, stigma, diversion, and confidence were calculated. Cross-tabulations and logistic regressions examined associations. Results: There were 775 surveys returned (response 7%, n = 11,123) with 390 community pharmacists completing the survey. Twenty-five percent practiced in a rural area. Common practice sites were chain or independent pharmacies (30% each). Ninety-seven percent had buprenorphine training, 50% from Accredited Continuing Pharmacy Education. Eighty percent reported that their pharmacy dispensed buprenorphine with 90% of rural pharmacists compared with 71% urban responding yes. Composite knowledge scores did not differ between urban or rural location (P > 0.05). Predictors of willingness to dispense buprenorphine were urban location (odds ratio, OR, 0.55; 95% confidence interval [CI], 0.34–0.91; P = 0.01), independent pharmacy (OR, 0.53; 95% CI, 0.30–0.94; P = 0.03), Accredited Continuing Pharmacy Education training (OR, 0.54; 95% CI, 0.34–0.87; P = 0.01), low stigma/diversion (OR, 0.51; 95% CI, 0.37–0.70; P = 0.00), and confidence in patient/provider interactions (OR, 0.14; 95% CI, 0.10–0.19; P = 0.00). Conclusions: Most survey pharmacists practice at pharmacies that dispense buprenorphine for opioid use disorder, with a larger proportion from rural pharmacies reporting availability. Pharmacists at independent pharmacies in urban locations have increased willingness to dispense buprenorphine, with urban pharmacists having lower perceptions of diversion compared with rural. Differences in buprenorphine availability, pharmacist willingness to dispense, and perceptions are opportunities for education. Limitations include one state, response bias, self-assessed competencies, and small samples.


  • Open Access

    Commercial and public payer opioid analgesic prescribing policies: a case study

    by Cynthia L. Arfken, Victoria Tutag Lehr

    Background: One strategy to address the high number of U.S. opioid-related deaths is to restrict high-risk or inappropriate opioid analgesic prescribing and dispensing. Federal and state laws and regulations have implemented restrictions but less is known about commercial and public payers’ policies aside from clinician anecdotal reports that these policies are increasing. To assess the number and types of policies with temporal trends, we examined commercial and public (Medicaid) payer policies in one state, Michigan, that has high opioid-related deaths and implemented opioid analgesic prescribing laws. Methods: Policies for seven large commercial payers and the public payer for 2012–2018 were reviewed and categorized by actions. Joinpoint regression was used to summarize temporal trends on number of policies for all payers and subgroups. Results: Across the 7 years, there were 529 action policies (75.57 (95% confidence intervals (CI) 35.93, 115.22) actions per year) with a range of 36 to 103 actions by payer. Limitations on number of days for initial prescriptions and prior authorizations were the most frequently implemented policy. The temporal trend showed a decline in new policies from 2012 to 2013 but a steady increase from 2014 to 2018 (average annual percent change or AAPC=29.6% (95% confidence intervals 13.2, 48.5%)). The public payer (n=47 policies) showed no increase in number of policies over time (AAPC=2.9% (95% CI -41.6, 61.6%). Conclusions: The eight commercial and public payers implemented many new policies to restrict opioid analgesic prescribing with a steady increase in the number of such policies implemented from 2014 to 2018. This case study documented that at least in one state with high opioid-related deaths and multiple commercial payers, new and different policies were increasingly implemented creating barriers to patient care. The impact of these policies is understudied, complicating recommendation of best practices.


  • Open Access

    Commercial and public payer opioid analgesic prescribing policies: A case study

    by Cynthia L Arfken, Victoria Tutag Lehr

    Background: One strategy to address the high number of U.S. opioid-related deaths is to restrict high-risk or inappropriate opioid analgesic prescribing and dispensing. Federal and state laws and regulations have implemented restrictions but less is known about commercial and public payers’ policies aside from clinician anecdotal reports that these policies are increasing. To assess the number and types of policies with temporal trends, we examined commercial and public (Medicaid) payer policies in one state, Michigan, that has high opioid-related deaths and implemented opioid analgesic prescribing laws. Methods: Policies for seven large commercial payers and the public payer for 2012-2018 were reviewed and categorized by actions. Joinpoint regression was used to summarize temporal trends on number of policies for all payers and subgroups. Results: Across the seven years, there were 529 action policies (75.57 (95% confidence intervals (CI) 35.93, 115.22) actions per year) with a range of 36 to 103 actions by payer. Limitations on number of days for initial and prior authorizations were the most frequently implemented policy.. The temporal trend showed a decline in new policies from 2012 to 2013 but a steady increase from 2014 to 2018 (average annual percent change or AAPC=29.6% (95% confidence intervals 13.2%, 48.5%)). The public payer (n=47 policies) showed no increase in number of policies over time (AAPC=2.9% (95% CI -41.6%, 61.6%).Conclusions: The eight commercial and public payers implemented many new policies to restrict opioid analgesic prescribing with a steady increase in the number of such policies implemented from 2014 to 2018. This case study documented that at least in one state with high opioid-related deaths and multiple commercial payers, new and different policies were increasingly implemented creating barriers to patient care. The impact of these policies is understudied, complicating recommendation of best practices.

  • Open Access

    Pharmacists' Perceived Knowledge and Expertise in Selected Pediatric Topics

    by Paul J. Munzenberger, Ron L. Thomas, Stephanie B. Edwin, Victoria Tutag-Lehr

    OBJECTIVES: The purpose of this study is to determine pharmacists' perceived knowledge and expertise required to make recommendations regarding selected pediatric topics.METHODS: A questionnaire was distributed to 400 pharmacists practicing in community, hospital, and home care settings. This instrument explored their perceived knowledge, expertise, and comfort in providing recommendations related to 38 pediatric topics. The impact of responder demographics on differences in perceived knowledge and expertise for each topic were evaluated.RESULTS: Ninety-five of 400 (24%) questionnaires were returned completed or partially completed. Forty-seven and 36 of responders practiced in the community or inpatient hospital setting, respectively. Seventy percent of responders reported that ≤ 40% of their patients were children. In general, responders believed they had the knowledge and expertise to make recommendations for the frequently occurring conditions or topics but not for the less familiar. Formal pediatric training was the most influential responder characteristic with a larger proportion having training that they believed enables them to have knowledge and expertise to make recommendations. Although less impressive, experience of more than 5 years and a community-based practice were also important factors.CONCLUSION: Additional training is beneficial in increasing the perceived knowledge and comfort of pharmacists making recommendations regarding pediatric patients.


  • Neonatal Facial Coding System Scores and Spectral Characteristics of Infant Crying During Newborn Circumcision

    by Victoria Tutag Lehr, Philip Sanford Zeskind, John P. Ofenstein, Eugene Cepeda, Indulekha Warrier, J. V. Aranda

    Objective To determine the relations between Neonatal Facial Coding System (NFCS) scores and measures of infant crying during newborn circumcision. Methods Video and audio recordings were made of infant facial activity and cry sounds, respectively, during the lysis phase of circumcisions of 44 healthy term males (PPPPPP<0.007). Discussion These data provide some of the first known evidence linking specific measures of infant crying with an independent, validated measure of pain.


  • Changing Patterns of Drug Utilization in a Neonatal Intensive Care Population

    by Wei Du, Indulekha Warrier, Victoria Tutag Lehr, Vali Salari, Enrique Ostrea, Jacob V. Aranda

    Newborns in the neonatal intensive care unit (NICU) typically are exposed to a large number of drugs and are especially vulnerable to adverse drug reactions. It is important to review changes in drug use patterns periodically in the NICU to identify newly introduced drugs as well as drugs with increasing use. The objective of this study was to determine the changes in drug utilization patterns over a 7-year period in an NICU population. Drug utilization of 2332 neonates treated at an intramural NICU between January 1, 1997 and December 31, 1998, and 2691 neonates between January 1, 2001 and June 30, 2004 was analyzed using chi-square tests, t tests, and linear regression. There was an increased utilization of antibiotics, central nervous system drugs, endocrine agents, cardiovascular and gastrointestinal drugs, and a decreased utilization of ophthalmic drugs. No changes in nutritional, biological, renal, and pulmonary drugs were observed. Some individual drug changes include an increased use of vancomycin, cefepime, caffeine, and a decreased use of morphine. Significant changes in drug utilization patterns in an NICU were observed during a 7-year period. These data are useful in monitoring drug resistance patterns, adverse drug reactions, and prioritizing areas of relevant therapeutic research and educational programs.